Homepage
Author:
Zymeworks Inc.
Posted Date:
May 15, 2026
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Zymeworks Inc.
May 15, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc.
May 13, 2026
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Zymeworks Inc.
May 8, 2026
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks Inc.
April 23, 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Zymeworks Inc.
April 20, 2026
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Zymeworks Inc.
April 16, 2026
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Zymeworks Inc.
April 9, 2026
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
Zymeworks Inc.
April 1, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks Inc.
March 30, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks Inc.
March 30, 2026
1
2
Next
